Michele Carbone to Pleural Neoplasms
This is a "connection" page, showing publications Michele Carbone has written about Pleural Neoplasms.
Connection Strength
8.648
-
Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019 09; 69(5):402-429.
Score: 0.687
-
Carbone M, Shimizu D, Napolitano A, Tanji M, Pass HI, Yang H, Pastorino S. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma. Oncotarget. 2016 Sep 13; 7(37):59314-59321.
Score: 0.566
-
Bononi A, Napolitano A, Pass HI, Yang H, Carbone M. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med. 2015 Oct; 9(5):633-54.
Score: 0.526
-
Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, Baumann F, Zhang YA, Gazdar A, Kanodia S, Tiirikainen M, Flores E, Gaudino G, Becich MJ, Pass HI, Yang H, Carbone M. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015 Apr; 10(4):565-76.
Score: 0.511
-
Carbone M, Gaudino G, Yang H. Recent insights emerging from malignant mesothelioma genome sequencing. J Thorac Oncol. 2015 Mar; 10(3):409-11.
Score: 0.508
-
Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, Yang H, Carbone M. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015 Jan; 36(1):76-81.
Score: 0.497
-
Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011 Aug 28; 43(10):1022-5.
Score: 0.399
-
Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009; 21(2):97-104.
Score: 0.332
-
Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008 Jun; 9(2-3):147-57.
Score: 0.323
-
Rivera Z, Strianese O, Bertino P, Yang H, Pass H, Carbone M. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med. 2008 Jul; 14(4):316-21.
Score: 0.320
-
Rdzanek M, Fresco R, Pass HI, Carbone M. Spindle cell tumors of the pleura: differential diagnosis. Semin Diagn Pathol. 2006 Feb; 23(1):44-55.
Score: 0.271
-
Carbone M, Bedrossian CW. The pathogenesis of mesothelioma. Semin Diagn Pathol. 2006 Feb; 23(1):56-60.
Score: 0.271
-
Pass HI, Bocchetta M, Carbone M. Evidence of an important role for SV40 in mesothelioma. Thorac Surg Clin. 2004 Nov; 14(4):489-95.
Score: 0.248
-
Hurtuk MG, Carbone M. A cytokeratin- and calretinin-negative staining sarcomatoid malignant mesothelioma. Anticancer Res. 2004 Sep-Oct; 24(5B):3097-102.
Score: 0.246
-
Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer. 2004 May-Jun; 28(3):93-174.
Score: 0.240
-
Carbone M, Rdzanek MA. Pathogenesis of malignant mesothelioma. Clin Lung Cancer. 2004 Apr; 5 Suppl 2:S46-50.
Score: 0.239
-
Carbone M, Rizzo P, Powers A, Bocchetta M, Fresco R, Krausz T. Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications. Anticancer Res. 2002 Nov-Dec; 22(6B):3443-8.
Score: 0.216
-
Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol. 2019 10; 14(10):1704-1717.
Score: 0.172
-
Carbone M, Guo Z, Mao W. Improving the Accuracy of?Mesothelioma Diagnosis in China. J Thorac Oncol. 2017 08; 12(8):e132.
Score: 0.150
-
Guo Z, Carbone M, Zhang X, Su D, Sun W, Lou J, Gao Z, Shao D, Chen J, Zhang G, Hu J, Chen K, Wang F, Pass HI, Yu H, Napolitano A, Yang H, Mao W. Improving the Accuracy of Mesothelioma Diagnosis in China. J Thorac Oncol. 2017 04; 12(4):714-723.
Score: 0.144
-
Pass HI, Goparaju C, Espin-Garcia O, Donington J, Carbone M, Patel D, Chen Z, Feld R, Cho J, Gadgeel S, Wozniak A, Chachoua A, Leighl N, Tsao MS, de Perrot M, Xu W, Liu G. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. J Thorac Oncol. 2016 06; 11(6):900-9.
Score: 0.136
-
Napolitano A, Antoine DJ, Pellegrini L, Baumann F, Pagano I, Pastorino S, Goparaju CM, Prokrym K, Canino C, Pass HI, Carbone M, Yang H. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Clin Cancer Res. 2016 06 15; 22(12):3087-96.
Score: 0.135
-
Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, Seepo S, Meyerson M, Pass HI. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015 Jan 15; 75(2):264-9.
Score: 0.125
-
Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012 Oct 11; 367(15):1417-27.
Score: 0.108
-
Ostroff RM, Mehan MR, Stewart A, Ayers D, Brody EN, Williams SA, Levin S, Black B, Harbut M, Carbone M, Goparaju C, Pass HI. Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One. 2012; 7(10):e46091.
Score: 0.108
-
Flores RM, Riedel E, Donington JS, Alago W, Ihekweazu U, Krug L, Rosenzweig K, Adusumilli PS, Carbone M, Pass HI. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol. 2010 Oct; 5(10):1649-54.
Score: 0.094
-
Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ, Testa JR, Pass HI, Carbone M, Steele C, Mossman BT. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci. 2010 Aug; 1203:7-14.
Score: 0.093
-
Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, Franzoso G, Lotze MT, Krausz T, Pass HI, Bianchi ME, Carbone M. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12611-6.
Score: 0.092
-
Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S, Aharonov R. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010 Mar 01; 70(5):1916-24.
Score: 0.090
-
Ivanov SV, Miller J, Lucito R, Tang C, Ivanova AV, Pei J, Carbone M, Cruz C, Beck A, Webb C, Nonaka D, Testa JR, Pass HI. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer. 2009 Feb 01; 124(3):589-99.
Score: 0.083
-
Bertino P, Carbone M, Pass H. Chemotherapy of malignant pleural mesothelioma. Expert Opin Pharmacother. 2009 Jan; 10(1):99-107.
Score: 0.083
-
Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg. 2008 Aug; 86(2):383-9; discussion 390.
Score: 0.081
-
Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008 Mar; 135(3):620-6, 626.e1-3.
Score: 0.078
-
Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2008 Jan; 85(1):265-72; discussion 272.
Score: 0.077
-
Carbone M, Strianese O, Theos K, Yang H. Mesothelioma. Hawaii Med J. 2007 Feb; 66(2):48-50.
Score: 0.073
-
Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, Mossman BT. Cellular and molecular parameters of mesothelioma. J Cell Biochem. 2006 Jul 01; 98(4):723-34.
Score: 0.070
-
Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005 Oct 13; 353(15):1564-73.
Score: 0.066
-
Wali A, Morin PJ, Hough CD, Lonardo F, Seya T, Carbone M, Pass HI. Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer. 2005 Apr; 48(1):19-29.
Score: 0.063
-
Pass HI, Liu Z, Wali A, Bueno R, Land S, Lott D, Siddiq F, Lonardo F, Carbone M, Draghici S. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res. 2004 Feb 01; 10(3):849-59.
Score: 0.059
-
Pass HI, Alimi M, Carbone M, Yang H, Goparaju CM. Mesothelioma Biomarkers: Discovery in Search of Validation. Thorac Surg Clin. 2020 Nov; 30(4):395-423.
Score: 0.047
-
Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ, Pass HI, Carbone M, Testa JR, Heintz NH, Mossman BT. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer. 2011 Sep 01; 129(5):1075-86.
Score: 0.024